Brooks Gabriel sold $25K of SLDB

H.C. Wainwright reiterated a Buy rating and $25 price target for Solid Biosciences (SLDB), citing EU orphan designation for its gene therapy SGT-212. The stock is down 9.2% over the past week, trading at $5.81. Analysts have revised earnings upwards, with a consensus Strong Buy rating. The company reported progress in its pipeline and a potential $200M stock offering.

Solid Biosciences (SLDB) received EU Orphan Drug Designation for SGT-212, a gene therapy for Friedreich's ataxia. The Phase 1b FALCON trial has dosed five participants with no serious adverse events. SGT-212 has also received U.S. FDA designations. SLDB stock is currently at $5.83, down 1.52%.

Solid Biosciences (SLDB) received EU orphan designation for SGT-212, a gene therapy for Friedreich’s ataxia. The company reported no serious adverse events in its Phase 1b trial with five participants. Initial data is expected in Q1 2027. SGT-212 also has U.S. Fast Track and Orphan Drug designations.

Portman David J. purchased 3,149,470 indirectly-held shares of LeonaBio, Inc. (LONA) at $3149.47 on 2026-10-26.

KAMFAR RAMIN purchased 178,677 indirectly-held shares of Bluerock Private Real Estate Fund (BPRE) at an average of $12.48 ($12.48–$12.48, $2.23M total) across 2 trades over 2026-10-26 to 2026-10-27.

Tether Global Investments Fund, S.I.C.A.F., S.A. purchased 100,000 indirectly-held shares of Gold.com, Inc. (GOLD) at an average of $39.27 ($38.96–$39.44, $3.93M total) across 3 trades over 2026-10-26 to 2026-10-28. Filed jointly with TPM, S.A. de C.V. (10% owner) and Devasini Giancarlo (10% owner).